

Yen Sun Technology Corp.

Notice of 2025 Annual Shareholders' Meeting

I. Information of the Meeting

Meeting type: Physical shareholders meeting

Time: 09:00 a.m., May 28, 2025 (Wednesday)

Location: No. 400, Renyong Rd., Renwu Dist., Kaohsiung City, Taiwan, ROC.

(Chunghwa Telecom Institute Kaohsiung Branch, Meeting Room 1211)

II. The agenda for the Meeting is as follows:

1. Report Matters

- (1) 2024 Business Report
- (2) 2024 Audit Committee's Review Report
- (3) 2024 Distributable Compensation for Employees and Directors
- (4) 2024 Earnings and Capital surplus Distribution of Cash Dividend
- (5) Implement Report for 2024 Private Placement of Common Share

2. Matters for Recognition

- (1) To accept 2024 Business Report and Financial Statements
- (2) To accept 2024 Earnings Distribution

3. Matters for Discussion

- (1) Amendment of the Articles of Incorporation
- (2) The Company plans to conduct a cash capital increase private placement of ordinary share

4. Extempore Motions

III. The Board of Directors has approved cash dividend distributions from earnings and capital surplus for \$1.6 and \$0.7 per share, respectively.

IV. The details of the Company's plan to conduct cash capital increase private placement of ordinary shares are as detailed in **Appendix**.

- V.** If the Company decides to hold a meeting under Article 172 of the Company Law, electronic files will be posted to the Market Observation Post System at <https://emops.twse.com.tw>. Please select "Shareholders' Meetings" under the "Electronic Books" tab, enter the year, and click "GO" to find the meeting files corresponding to Company code.
- VI.** Pursuant to Article 165 of the Company Act, the Company hereby closes the share transfer registration from March 30, 2025 to May 28, 2025.
- VII.** Please find enclosed the "Notice of Attendance" and "Proxy Statement." If you intend to personally attend the meeting, please sign or place your seal in the "Registration Card" column. Shareholders may sign or place their seal in the "Proxy Statement" column to appoint a proxy to attend the meeting on his or her behalf and execute power of attorney in writing. Please fill in the "Proxy Statement" and deliver to the Company's stock agency, Grand Fortune Securities Co., Ltd. Transfer Agent, no later than 5 days prior to the meeting date; if the entrusted agent has not received the attendance sign-in card the day before the meeting, please bring the identity document to the venue on the day of the meeting to attend.
- VIII.** The company will compile a summary statement of the relevant information provided by shareholders through solicitation of the proxy and disclose the content in the website of Securities & Futures Institute (SFI) no later than April 25, 2025. Shareholders can navigate to SFI's web page (<https://free.sfi.org.tw>) to view relevant information. (TWSE code: 6275)
- IX.** Shareholders may exercise his/her/its voting rights by way of electronic transmission during the period from April 26, 2025 to May 25, 2025. Please log in the "Stockvote" (<https://www.stockvote.com.tw>) of Taiwan Depository & Clearing Corporation (TDCC) and vote in.
- X.** The Transfer Agency Department of Grand Fortune Securities Co., Ltd. is the proxy tallying and verification institution for this Annual meeting.

It is highly appreciated that you handle the matters accordingly.

Sincerely,

Board of Directors

Yen Sun Technology Corp.

Appendix

The details of the Company's plan to conduct cash capital increase private placement of ordinary shares are as follow:

1. In order to enrich working capital, strengthen the financial structure and support other capital needs for the Company's long-term operational development, and taking into account timeliness and convenience of the cost of raising funds and introducing strategic partners, the Company intends to submit a proposal to the shareholders' meeting to authorize the board of directors to raise no more than 20,000,000 shares of ordinary shares through private placement, and will be processed in 2 installments within 1 year from the date of resolution of the shareholders' meeting.
2. In accordance with Article 43-6 of the R.O.C. Securities and Exchange Act, fundraising and conducting principles for cash capital increase and issuance of ordinary shares through private placement:
 - A. The Pricing Basis and Reasonableness:
 - a. The reference price for issuing ordinary shares in the Proposed Private Placement will based on (1.) the simple arithmetical average closing price of the ordinary shares of the Company on any of the first, third or fifth trading day prior to the pricing date, after deducting the value of bonus shares issued as stock dividends and cash dividends, and adding back the value of the shares canceled in connection with capital reduction. or (2.) the simple arithmetical average closing price of the ordinary shares of the Company for thirty trading days prior to the pricing date, after deducting the value of bonus shares issued as stock dividends and cash dividends, and adding back the value of shares cancelled in connection with capital reduction; the reference price is set to be the price determined by whichever is higher.
 - b. The actual pricing date and price of this private placement of ordinary shares shall be based on the above-mentioned principles and shall not be lower than the reference price by 80%. It is proposed to the shareholders' meeting to authorize the board of directors to set the price in the future with specific person's situations and market conditions.

- c. The aforementioned private placement ordinary share subscription price is determined in accordance with the provisions of "Directions for Public Companies Conducting Private Placements of Securities"; taking into account the Company's future prospects and the transfer time, objects and quantity of private placement securities, there are strict restrictions, and private placement securities will not be listed on the OTC market within three years, and its liquidity is poor. Therefore, the setting of this price should be reasonable.
- B. The method and purpose of investors selection, necessity and expected benefits:
 - a. Selection method of investors: The objects of this private placement are specific person that comply with Article 43-6 of the Act and relevant interpretations from the competent authorities, and can bring benefits to the Company's long-term development, enhance competitiveness, and existing shareholders' rights and interests. Priority will be given to strategic investors who can assist the Company in developing new markets, expand its operating scale and directly or indirectly benefit the Company's future operations.
 - b. Selection purpose, necessity and expected benefits: In response to the Company's operational development needs, it is planned to directly or indirectly assist the Company to develop new markets, add new product lines and expand operating scale through strategic investors, in order to strengthen the Company's competition capabilities and improve operational efficiency.
 - c. The relationship between the subscriber and the Company: The Company has not yet decided on the applicants. The actual selection of applicants is subject to the shareholders' meeting to authorize the board of directors to handle it with full authority.
- C. The justification, issue amount, use and anticipated benefits for the proposed private placement:
 - a. The Reasons for not Adopting a Public Offering: To ensure a timely and feasible fundraising while reducing the cost of capital effectively, it is proposed that the Company raises the fund from specific investors through a private placement to increase the flexibility and efficiency of fund raising. In addition, the securities issued in the Proposed Private Placement are subject to free share transfer restriction for a period of 3 years, so that a long term partnership between the Company and strategic investors can be secured.

b. Estimated rounds of Private Placement, Intended Usage of Funds, and Expected Benefits:

Round	Number of Shares	Intended Usage of Funds	Expected Benefits
First Round	10,000,000	The funds raised in this offering will be used to strengthen working capital, enhance the Company’s financial structure, and support other funding needs related to the Company’s long-term operational development.	It is expected that the capital injection will improve the Company’s financial structure, strengthen competitiveness, and enhance operational efficiency, thereby having a positive impact on shareholders’ equity.
Second Round	10,000,000		
With respect to the aforementioned first and second planned private placements of common shares, the Company may, at the time of each actual placement, combine any previously unissued shares and/or shares planned for issuance in subsequent rounds, in whole or in part. However, the total number of shares issued shall not exceed 20,000,000 shares.			

3. This cash capital increase private placement of common shares will be issued in a non-entity manner. Except for the restriction on transfer within 3 years after delivery in accordance with Article 43-8 of the Act, the rights and obligations of the ordinary shares in this private placement are the same as those of the Company's issued ordinary shares. The private placement of common shares and the subsequent allotment of common shares authorizes the board of directors to apply for supplementary issuance and OTC trading in accordance with relevant laws and regulations 3 years after from the date of delivery of the private placement of common shares.
4. The Company had no major changes in its operating rights 1 year before the board of directors decided to conduct private placement. As of January 31, 2025, the Company has 77,909,257 issued shares (766,000 treasury shares have been deducted). After adding in the 20,000,000 shares proposed for this private placement, based on the full issuance, it is expected that the paid-in capital will increase to 97,909,257 shares. This transaction After the private placement, the total number of private placement shares is expected to account for 20.43% of the post-private placement equity.
5. If the planned multiple tranches of private placements cannot be completed within the designated period, or if there is no plan to continue with additional tranches within the remaining time, yet the original plan remains feasible, it shall be deemed that the payment for the privately placed securities has been fully received.
6. After the resolution of the shareholders' meeting for this cash capital increase in private placement of ordinary shares is passed, in addition to the private placement pricing ratio, it is planned to include the number of private placement shares, price, fund utilization plan, fund use and progress, expected benefits and other related matters, etc. the shareholders' meeting is requested

to authorize the board of directors to handle the matter with full authority based on the Company's actual needs, market conditions and relevant laws. If subsequent changes or modifications are required by the competent authority or based on operational evaluation or changes in objective circumstances or laws, the board of directors will be authorized to handle it with full authority.

7. In order to successfully complete this financing plan, the shareholders' meeting is requested to authorize the chairman or his designated person to discuss and sign the contracts and documents related to the private placement of cash capital increase and issuance of ordinary shares on behalf of the Company, and to handle the matters required for capital increase and issuance of common shares for the Company.
8. Whether the independent directors have objections or reservations: None.
9. For information related to this private placement of securities, please refer to the "Private Placement Zone" of the MOPS: (Website: <https://mops.twse.com.tw>, "Market Type", select "Listed" and "Company Code or Abbreviation" and type "6275" to query) and Company's website (website: <https://www.ystech.com.tw>).